Results

1–10 of 12 results for Archway

End-of-Study Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With nAMD
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2022
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2021
Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS)
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2021
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial
John W. Kitchens, MD
Annual Meeting Talks
2021
Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2021
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab: From PRN Refills in Phase 2 Ladder to Fixed 24-Week Refills In Phase 3 Archway
Dilsher S. Dhoot, MD
Annual Meeting Talks
2020
Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD
Peter A. Campochiaro, MD
Annual Meeting Talks
2020
Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD
Carl C. Awh, MD, FASRS
Updates from the Field
2021
Pharmacokinetic Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 3 Archway Trial
Peter A. Campochiaro, MD
Updates from the Field
2021
Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD
Peter A. Campochiaro, MD
Updates from the Field
2020